ReviewNeurologic clinics2015
Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.
Review in Neurologic clinics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Rehabilitation in Amyotrophic Lateral Sclerosis: Recommendations for Clinical Practice and Further Research.Journal of clinical medicine · 2025Review
- High doses of opioids usage for amyotrophic lateral sclerosis patients with non-invasive ventilation.Acta neurologica Belgica · 2024Article
- Telehealth for amyotrophic lateral sclerosis in a multidisciplinary service in a Brazilian reference center.Arquivos de neuro-psiquiatria · 2023Article
- A Multi-Center Cohort Study on Characteristics of Pain, Its Impact and Pharmacotherapeutic Management in Patients with ALS.Journal of clinical medicine · 2021Article
- Impact of the Chin-Down Posture on Temporal Measures of Patients With Dysphagia: A Pilot Study.American journal of speech-language pathology · 2021Article
- The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS).BMC medicine · 2021Review
- Amyotrophic lateral sclerosis and intestinal microbiota-toward establishing cause and effect.Gut microbes · 2020Review
- ALS: Management Problems.Neurologic clinics · 2020Review
- Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials.Statistics in biopharmaceutical research · 2019Article
- Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis.PloS one · 2019Article
- Continuous noninvasive ventilation for respiratory failure in patients with amyotrophic lateral sclerosis: current perspectives.Degenerative neurological and neuromuscular disease · 2018Review
- Edematous Hyponatremia Treated with Tolvaptan in a Patient with Amyotrophic Lateral Sclerosis.Electrolyte & blood pressure : E & BP · 2017Article
- ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Frontiers in aging neuroscience · 2017Review
- Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach.Journal of multidisciplinary healthcare · 2017Review
- Revisiting the Term Neuroprotection in Chronic and Degenerative Diseases.Neurology international · 2016Article
- Non-Motor Features of Amyotrophic Lateral Sclerosis: A Clinic-based Study.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The number of available symptomatic treatments has markedly enhanced the care of patients with amyotrophic lateral sclerosis (ALS). Once thought to be untreatable, patients with ALS today clearly benefit from multidisciplinary care. The impact of such care on the disease course, including rate of progression and mortality, has surpassed the treatment effects commonly sought in clinical drug trials. Unfortunately, there are few randomized controlled trials of medications or interventions addressing symptom management. In this review, the authors provide the level of evidence, when available, for each intervention that is currently considered standard of care by consensus opinion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.